ATE526990T1 - Genetisch modifizierte zellen, welche einen tgf- beta inhibitor exprimieren, wobei die zellen lungenkrebszellen sind - Google Patents

Genetisch modifizierte zellen, welche einen tgf- beta inhibitor exprimieren, wobei die zellen lungenkrebszellen sind

Info

Publication number: ATE526990T1
Authority: AT; Austria
Prior art keywords: cells; lung cancer; genetically modified; tgf; beta inhibitor
Prior art date: 2000-03-31

Application number

AT01926498T

Other languages

English (en)

Inventor

Habib Fakhrai

Original Assignee

Novarx

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-03-30

Publication date

2011-10-15

2001-03-30 Application filed by Novarx filed Critical Novarx

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526990T1 publication Critical patent/ATE526990T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 2
206010058467 Lung neoplasm malignant Diseases 0.000 title 1
201000005202 lung cancer Diseases 0.000 title 1
208000020816 lung neoplasm Diseases 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
206010041067 Small cell lung cancer Diseases 0.000 abstract 2
208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
208000000587 small cell lung carcinoma Diseases 0.000 abstract 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
230000002068 genetic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Oncology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT01926498T 2000-03-31 2001-03-30 Genetisch modifizierte zellen, welche einen tgf- beta inhibitor exprimieren, wobei die zellen lungenkrebszellen sind ATE526990T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19349700P	2000-03-31	2000-03-31
PCT/US2001/010339 WO2001074404A2 (en)	2000-03-31	2001-03-30	Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor

Publications (1)

Publication Number	Publication Date
ATE526990T1 true ATE526990T1 (de)	2011-10-15

Family

ID=22713877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01926498T ATE526990T1 (de)	2000-03-31	2001-03-30	Genetisch modifizierte zellen, welche einen tgf- beta inhibitor exprimieren, wobei die zellen lungenkrebszellen sind

Country Status (8)

Country	Link
EP (2)	EP1267945B8 (de)
JP (2)	JP5079962B2 (de)
AT (1)	ATE526990T1 (de)
AU (1)	AU2001253031A1 (de)
DK (1)	DK1267945T3 (de)
ES (1)	ES2373431T3 (de)
PT (1)	PT1267945E (de)
WO (1)	WO2001074404A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7101543B2 (en)	2000-03-31	2006-09-05	Novarx	Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
US8293252B2 (en) *	2006-12-20	2012-10-23	Novarx Corporation	Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
JP6410237B2 (ja) *	2012-11-09	2018-10-24	マルコアーケッティ	拡散性因子および癌細胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5116742A (en)	1986-12-03	1992-05-26	University Patents, Inc.	RNA ribozyme restriction endoribonucleases and methods
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en)	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
ES2144426T3 (es) *	1991-10-25	2000-06-16	Sidney Kimmel Cancer Ct	Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
US5772995A (en) *	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
US5824655A (en) *	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy

2001
- 2001-03-30 AT AT01926498T patent/ATE526990T1/de active
- 2001-03-30 ES ES01926498T patent/ES2373431T3/es not_active Expired - Lifetime
- 2001-03-30 DK DK01926498.5T patent/DK1267945T3/da active
- 2001-03-30 EP EP01926498A patent/EP1267945B8/de not_active Expired - Lifetime
- 2001-03-30 PT PT01926498T patent/PT1267945E/pt unknown
- 2001-03-30 AU AU2001253031A patent/AU2001253031A1/en not_active Abandoned
- 2001-03-30 WO PCT/US2001/010339 patent/WO2001074404A2/en not_active Ceased
- 2001-03-30 EP EP10178154A patent/EP2314322A1/de not_active Withdrawn
- 2001-03-30 JP JP2001572145A patent/JP5079962B2/ja not_active Expired - Fee Related
2012
- 2012-06-21 JP JP2012139658A patent/JP2012176994A/ja active Pending

Also Published As

Publication number	Publication date
JP2003528930A (ja)	2003-09-30
JP5079962B2 (ja)	2012-11-21
WO2001074404A2 (en)	2001-10-11
WO2001074404A3 (en)	2002-10-17
EP1267945A2 (de)	2003-01-02
EP1267945B1 (de)	2011-10-05
PT1267945E (pt)	2011-12-28
EP2314322A1 (de)	2011-04-27
JP2012176994A (ja)	2012-09-13
DK1267945T3 (da)	2011-10-31
AU2001253031A1 (en)	2001-10-15
EP1267945B8 (de)	2012-03-21
ES2373431T3 (es)	2012-02-03

Similar Documents

Publication	Publication Date	Title
NO2022001I1 (no)	2022-01-06	Pazopanib
WO2005030121A3 (en)	2005-11-10	Compounds, compositions and methods
WO2005042692A3 (en)	2005-09-09	A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
EP2281876A3 (de)	2012-04-11	Verfahren zur Kontrolle von Schädligen durch Verwendung von RNAi-Technologie
PA8531501A1 (es)	2003-06-30	Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona
TR200000481T2 (tr)	2000-06-21	N-Alkonoilfenilalenin türevleri.
ATE450251T1 (de)	2009-12-15	Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
WO2007067992A3 (en)	2007-11-29	Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2005097175A3 (en)	2009-11-19	Human glp-1 mimetibodies, compositions, methods and uses
WO2001019859A3 (en)	2002-05-10	LEPIDOPTERAN-ACTIVE BACILLUS THURINGIENSIS δ-ENDOTOXIN COMPOSITIONS AND METHODS OF USE
ATE556714T1 (de)	2012-05-15	Doppelsträngige oligonukleotide
AU2002214596A1 (en)	2002-04-22	Methods and compositions for nucleic acid delivery
DK1526840T3 (da)	2008-11-03	Nanopartikler til DNA administration til et målorgan
WO2007065010A3 (en)	2007-11-29	Anti-angiogenesis compounds
WO2006018836A3 (en)	2007-05-18	Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
EP1607088A4 (de)	2009-12-09	Zusammensetzung mit kontrollierter freisetzung
WO2001057058A3 (de)	2003-02-13	Nachweis von differenzieller genexpression
WO2001096606A3 (en)	2003-12-04	Identification of genes and compounds for treatment of cancer
UA90698C2 (en)	2010-05-25	Triazole substituted aminobenzophenone compounds
WO2005034876A3 (en)	2005-10-06	Use of cell lines to produce active therapeutic proteins
ATE526990T1 (de)	2011-10-15	Genetisch modifizierte zellen, welche einen tgf- beta inhibitor exprimieren, wobei die zellen lungenkrebszellen sind
WO2003076610A3 (fr)	2004-04-08	Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
MX2008001597A (es)	2008-04-04	Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
AR028316A1 (es)	2003-05-07	Gen de masa nsea elevada del cromosoma 11q13.3
BRPI0519267A2 (pt)	2009-01-06	derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo

Legal Events

Date

Code

Title

Description

2012-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1267945

Country of ref document: EP